Mori, Keiichiro http://orcid.org/0000-0002-6147-6569
Schuettfort, Victor M.
Katayama, Satoshi
Laukhtina, Ekaterina
Pradere, Benjamin
Quhal, Fahad
Sari Motlagh, Reza
Mostafaei, Hadi
Grossmann, Nico C.
Rajwa, Pawel
Teoh, Jeremy YC.
Resch, Irene
Fajkovic, Harun
Moschini, Marco
D’andrea, David
Abufaraj, Mohammad
Karakiewicz, Pierre I.
Lotan, Yair
Scherr, Douglas
Egawa, Shin
Compérat, Eva
Shariat, Shahrokh F.
,
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 17 October 2021
Accepted: 21 February 2022
First Online: 26 March 2022
Disclosures
: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer (Grant No. 2002-09-06); methods to determine prognosis after therapy for bladder cancer (Grant No. 2003-06-19); prognostic methods for patients with prostatic disease (Grant No. 2004-08-05); Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma (Grant No. 2010-07-20). He has a consulting or advisory role for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Jansen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, Takeda, Urogen, and Wolff. Yair Lotan is a consultant for Nanorobotics (consultation starting 5/21), C2I genomics (consultaation starting 10/20), Photocure: Consultant/advisor, scientific study or trial, Astra-Zeneca: Consultant/advisor, Merck: consultant/advisor, Fergene: Consultant, Abbvie: consultant (starting 6/20), Cleveland Diagnostics; consultant, Nucleix consultant, Ambu: consultant, Seattle Genetics: consultant (agreement 12/20), Hitachi: 1/20, Ferring Research: 2/20, verity pharmaceuticals, virtuoso surgical (started 3/21), Nanorobot (started 6/21), Stimit (started 7/21). <i>Research</i> Abbott: Scientific study or trial completed 3/19, Cepheid: Scientific study or trial, Pacific Edge: Scientific study or trial, FKD: Scientific study or trial (completed 2019), MDxHealth: Scientific study or trial, Biocancell: Scientific study or trial (ended 1/20), GenomeDx Biosciences, Inc.: Scientific study or trial, Storz: scientific Study.